Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
|
|
First Wave BioPharma, Inc. (AZRX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/25/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 08/18/2023 |
8-K
| Quarterly results |
| 07/21/2023 |
8-K
| Quarterly results |
| 07/13/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 06/16/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modifications to Rights of Secu...|
Docs:
|
"COMMON STOCK PURCHASE WARRANT FIRST WAVE BIOPHARMA, InC. Warrant Shares: __________ Initial Exercise Date: June 13, 2023 THIS COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time at any time on or after June 13, 2023 and on or prior to 5:00 p.m. on June 13, 2028 but not thereafter, to subscribe for and purchase from First Wave BioPharma, Inc., a Delaware corporation , up to _____ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 .           Definitions . In addit...",
"Annex A – Representations and Warranties",
"First Wave BioPharma Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $2.4 Million Gross Proceeds Priced At-the-Market BOCA RATON, Fla., June 13, 2023 -- First Wave BioPharma, Inc. , a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases, today announced it has entered into agreements with certain holders of its existing warrants exercisable for 1,681,667 shares of its common stock, in the aggregate, to exercise their warrants at a reduced exercise price of $1.15 per share, in exchange for new warrants as described below. The aggregate gross proceeds from the exercise of the existing warrants is expected to total approximately $2.4 million, before deducting financial ..." |
|
| 04/21/2023 |
8-K
| Quarterly results |
| 03/15/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ...|
Docs:
|
"PRE-FUNDED COMMON STOCK PURCHASE WARRANT FIRST WAVE BIOPHARMA, InC. Warrant Shares: ________ Issue Date: ______, 2023 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT certifies that, for value received, ___________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof until this Warrant is exercised in full but not thereafter, to subscribe for and purchase from First Wave BioPharma, Inc., a Delaware corporation , up to _____ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . Capitalized terms used and not otherwise defined herein shall have the meanings ...",
"COMMON STOCK PURCHASE WARRANT FIRST WAVE BIOPHARMA, InC. Warrant Shares: __________ Initial Exercise Date: _______, 2023 THIS COMMON STOCK PURCHASE WARRANT certifies that, for value received, ________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time at any time on or after _____, 2023 and on or prior to 5:00 p.m. on _____, 2028 but not thereafter, to subscribe for and purchase from First Wave BioPharma, Inc., a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . In addition to the terms defined elsewhere in this Warrant, the following term...",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of March __, 2023, between First Wave BioPharma, Inc., a Delaware corporation , and each purchaser identified on the signature pages hereto . WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to Section 4 under the Securities Act , and Rule 506 promulgated thereunder, the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, Securities of the Company as more fully described in this Agreement. NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and...",
"Schedule 6(b)",
"First Wave BioPharma Announces $4.0 Million Private Placement Priced At-The-Market under Nasdaq Rules BOCA RATON, Fla, March 13, 2023 – First Wave BioPharma, Inc. , a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases, today announced that it has entered into a definitive agreement with a certain institutional investor for the issuance and sale of 1,023,018 shares of common stock and warrants to purchase up to 2,046,036 shares of common stock at an offering price of $3.91 per share and accompanying warrant, in a private placement priced at-the-market under Nasdaq rules. The warrants are exercisable immediately upon issuance, have a term of five years and an exercise price of $3.66 per share. The private..." |
|
| 02/07/2023 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
| 01/17/2023 |
8-K
| Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea... |
| 12/20/2022 |
8-K
| Quarterly results |
| 12/16/2022 |
8-K
| Quarterly results |
| 12/02/2022 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 11/28/2022 |
8-K
| Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...|
Docs:
|
"FIRST WAVE BIOPHARMA ANNOUNCES DISTRIBUTION OF SERIES F PREFERRED STOCK TO HOLDERS OF ITS COMMON STOCK BOCA RATON, Fla., November 25, 2022 — First Wave BioPharma, Inc. , a clinical-stage biopharmaceutical company specializing in the development of targeted, non-system therapies for gastrointestinal diseases, today announced that its Board of Directors declared a dividend of 0.001 of a share of newly-designated Series F Preferred Stock, par value $0.0001 per share, for each outstanding share of the Company’ s common stock held of record as of 5:00 p.m. Eastern Time on December 5, 2022. The outstanding shares of Series F Preferred Stock will vote together with the outstanding shares of the Company’ s common stock, as a single class, exclusively with respect to a reverse stock split, as well ..." |
|
| 11/22/2022 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ...|
Docs:
|
"PRE-FUNDED COMMON STOCK PURCHASE WARRANT FIRST WAVE BIOPHARMA, InC. Warrant Shares: _______ Issue Date: _______, 2022 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof until this Warrant is exercised in full but not thereafter, to subscribe for and purchase from First Wave BioPharma, Inc., a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . Capitalized terms used and not otherwise defined herein shall have the meanin...",
"COMMON STOCK PURCHASE WARRANT FIRST WAVE BIOPHARMA, InC. Warrant Shares: _______ Issue Date: _______, 2022 THIS COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time at any time on or after the Shareholder Approval Date and on or prior to 5:00 p.m. on the five and one-half year anniversary of the Initial Exercise Date but not thereafter, to subscribe for and purchase from First Wave BioPharma, Inc., a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. For purposes hereof, “ Shareholder Appr...",
"Armistice Capital Master Fund Ltd.",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of November [__], 2022, between First Wave BioPharma, Inc., a Delaware corporation , and each purchaser identified on the signature pages hereto . WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to Section 4 under the Securities Act , and Rule 506 promulgated thereunder, the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, Securities of the Company as more fully described in this Agreement. NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Compan...",
"Schedule 6(b)",
"First Wave BioPharma, Inc. Announces Private Placement BOCA RATON, Fla., November 21, 2022 – First Wave BioPharma, Inc. , a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases, today announced that it has entered into a securities purchase agreement with a single institutional investor for the issuance and sale of pre-funded warrants to purchase up to an aggregate of 4,166,667 shares of its common stock and warrants to purchase up to an aggregate of 8,333,334 shares of its common stock at an effective purchase price of $0.60 per share and accompanying warrants in a private placement for aggregate gross proceeds of approximately $2.5 million, before deducting placement agent fees and other offering ..." |
|
| 10/12/2022 |
8-K
| Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits Inte...|
Docs:
|
"PRE-FUNDED COMMON STOCK PURCHASE WARRANT FIRST WAVE BIOPHARMA, InC. Warrant Shares: Issue Date: , 2022 Initial Exercise Date: , 2022 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT certifies that, for value received, Armistice Capital Master Fund, Ltd. or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above and until this Warrant is exercised in full but not thereafter, to subscribe for and purchase from First Wave BioPharma, Inc., a Delaware corporation , up to _________ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . In addition to the terms...",
"SERIES E COMMON STOCK PURCHASE WARRANT FIRST WAVE BIOPHARMA, InC. Warrant Shares: Issue Date: , 2022 Initial Exercise Date: , 2022 THIS SERIES E COMMON STOCK PURCHASE WARRANT certifies that, for value received, Armistice Capital Master Fund, Ltd. or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after _________, 2022 and on or prior to 5:00 p.m. on _________, 2027 but not thereafter, to subscribe for and purchase from First Wave BioPharma, Inc., a Delaware corporation , up to _________ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . In addition to the terms defined ...",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of October 6, 2022, between First Wave BioPharma, Inc., a Delaware corporation , and each purchaser identified on the signature pages hereto . WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act , the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement. NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and each Purc...",
"FIRST WAVE BIOPHARMA, INC. ANNOUNCES PRICING OF $6.0 MILLION PUBLIC OFFERING BOCA RATON, Fla., Oct. 06, 2022 -- First Wave BioPharma, Inc. , a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases, today announced the pricing of a public offering of 3,438,396 shares of its common stock and warrants to purchase up to an aggregate of 3,438,396 shares of its common stock at an offering price to the public of $1.745 per share and associated warrant. The warrants will have an exercise price of $1.62 per share, are exercisable immediately upon issuance, and will expire five years following the date of issuance. The closing of the offering is expected to occur on or about October 11, 2022, subject to the sa...",
"First Wave BioPharma, Inc. Announces Closing of $6.0 Million Public Offering BOCA RATON, Fla., October 11, 2022 – First Wave BioPharma, Inc. , a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases, today announced the closing of its previously announced public offering of 3,438,396 shares of its common stock and warrants to purchase up to an aggregate of 3,438,396 shares of its common stock at an offering price to the public of $1.745 per share and associated warrant. The warrants have an exercise price of $1.62 per share, are exercisable immediately upon issuance, and will expire five years following the date of issuance. H.C. Wainwright & Co. acted as the exclusive placement agent for the offerin..." |
|
| 08/25/2022 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Amendments to Articles o...|
Docs:
|
"Certificate of Amendment to the Amended and Restated Certificate of Incorporation of First Wave BioPharma, Inc.",
"First Wave BioPharma, Inc. Announces Reverse Stock Split BOCA RATON, Fla., August 25, 2022 – First Wave BioPharma, Inc. , a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases, today announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 30 pre-split shares. First Wave’ s common stock will continue to be traded on the NASDAQ Capital Market under the symbol FWBI and will begin trading on a split-adjusted basis when the market opens on Friday, August 26, 2022, under a new CUSIP number, 33749P200. At the effective time of the reverse stock split, every thirty shares of First Wave’ s issued and outstanding common stock will be converted ..." |
|
| 07/29/2022 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 07/18/2022 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation ...|
Docs:
|
"FIRST WAVE BIOPHARMA, Inc. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES D CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE delaware GENERAL CORPORATION LAW The undersigned, James Saperstein, does hereby certify that: 1. The undersigned is the President and Chief Executive Officer of First Wave BioPharma, Inc., a Delaware corporation . 2. The Corporation is authorized to issue 10,000,000 shares of preferred stock, $0.0001 par value per share. 3. The following resolutions were duly adopted by the board of directors of the Corporation : WHEREAS, the Amended and Restated Certificate of Incorporation of the Corporation, as amended , provides for a class of its authorized stock known as preferred stock, consisting of 10,000,000 shares, $0.0001 par value p...",
"FIRST WAVE BIOPHARMA, Inc. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES E CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE delaware GENERAL CORPORATION LAW The undersigned, James Saperstein, does hereby certify that: 1. The undersigned is the President and Chief Executive Officer of First Wave BioPharma, Inc., a Delaware corporation . 2. The Corporation is authorized to issue 10,000,000 shares of preferred stock, $0.0001 par value per share. 3. The following resolutions were duly adopted by the board of directors of the Corporation : WHEREAS, the Amended and Restated Certificate of Incorporation of the Corporation, as amended , provides for a class of its authorized stock known as preferred stock, consisting of 10,000,000 shares, $0.0001 par value p...",
"SERIES D COMMON STOCK PURCHASE WARRANT FIRST WAVE BIOPHARMA, InC. Warrant Shares: _______ Issue Date: _______, 2022 THIS SERIES D COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Reverse Stock Split Date and on or prior to 5:00 p.m. on the fifth anniversary of the Initial Exercise Date but not thereafter, to subscribe for and purchase from First Wave BioPharma, Inc., a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . Capitalized terms used a...",
"PLACEMENT AGENT SERIES D COMMON STOCK PURCHASE WARRANT FIRST WAVE BIOPHARMA, InC. Warrant Shares: _______ Issue Date: July 15, 2022 THIS PLACEMENT AGENT SERIES D COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Reverse Stock Split Date and on or prior to 5:00 p.m. on the fifth anniversary of the Initial Exercise Date but not thereafter, to subscribe for and purchase from First Wave BioPharma, Inc., a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. This Warrant is be...",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of July 15, 2022, between First Wave BioPharma, Inc., a Delaware corporation , and each purchaser identified on the signature pages hereto . WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to Section 4 under the Securities Act of 1933, as amended and Rule 506 thereunder, the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, Securities of the Company as more fully described in this Agreement. NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Compan...",
"SELLING STOCKHOLDERS The common stock being offered by the selling stockholders are those previously issued to the selling stockholders, and those issuable to the selling stockholders, upon conversion of preferred stock or the exercise of warrants. For additional information regarding the issuances of those shares of preferred stock and warrants and common stock issued and issuable upon conversion of the preferred stock and the exercise of the warrants, see “Private Placement of Shares of Preferred Stock and Warrants” above. We are registering the shares of common stock in order to permit the selling stockholders to offer the shares for resale from time to time. Except for the ownership of our securities, the selling stockholders have not had any material relationship with us within the pa...",
"First Wave BioPharma, Inc. Announces Private Placement BOCA RATON, Fla., July 15, 2022 – First Wave BioPharma, Inc. , a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases, today announced that it has entered into a securities purchase agreement with several institutional accredited investors for the issuance and sale of an aggregate of 150 shares of its Series D Convertible Preferred Stock, stated value $1,000 per share, 150 shares of its Series E Convertible Preferred Stock, stated value $1,000 per share, and Series D Warrants to purchase up to 2,000,000 shares of its common stock in a private placement for aggregate gross proceeds of approximately $300,000, before deducting placement agent fees ..." |
|
| 07/15/2022 |
8-K
| Quarterly results |
| 07/07/2022 |
8-K
| Quarterly results |
| 07/07/2022 |
8-K
| Quarterly results |
| 06/17/2022 |
8-K
| Quarterly results |
| 05/27/2022 |
8-K
| Quarterly results |
| 05/27/2022 |
8-K
| Quarterly results |
| 05/16/2022 |
8-K
| Quarterly results |
| 05/12/2022 |
8-K
| Quarterly results |
| 05/05/2022 |
8-K
| Quarterly results |
| 05/03/2022 |
8-K
| Quarterly results |
| 04/29/2022 |
8-K
| Quarterly results |
| 04/06/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/01/2022 |
8-K
| Quarterly results |
| 02/17/2022 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Departure of Directors o... |
| 02/07/2022 |
8-K
| Quarterly results |
| 01/14/2022 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders... |
|
|
|